A Study to Determine the Satisfaction With Actonel in Postmenopausal Women With Osteoporosis
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
The study in the labeled and real conditions of prescription of Actonel will investigate the
satisfaction of patients with its new formulation: 35 mg Once A Week. The study will also
measure response rates in CTX (the C-telopeptide of type I collagen) at baseline and after 12
weeks of treatment with risedronate 35 mg Once A Week.